Bedrijfsoverzicht
Zymeworks Inc. is a biotechnology enterprise dedicated to the development of advanced biotherapeutics designed to treat severe conditions including cancer, inflammation, and various autoimmune diseases. The company leverages proprietary technological platforms, specifically the Azymetric multispecific antibody platform and a Drug Conjugate platform featuring a suite of proprietary cytotoxins, to advance its therapeutic pipeline within the competitive healthcare landscape. Operating in the broader Healthcare sector and the specialized Biotechnology industry, Zymeworks focuses on high-risk, high-reward research and development activities typical of early-stage pharmaceutical firms. The company currently holds a market capitalization of $1.96B, generates annual revenue of $105.97M, and employs a workforce of 264 individuals. These financial figures indicate a mid-to-large capitalization entity that has achieved significant revenue scale despite operating in a capital-intensive industry where profitability often lags behind revenue generation during the research phase.
Financiële gezondheid
Zymeworks reported a trailing twelve-month revenue of $105.97M, yet the company recorded a net income loss of $-81,130,000 and an EBITDA of $-84,824,000 during the same period. The substantial gap between the generated revenue and the negative net income reveals a cost structure characterized by heavy research and development expenditures, general administrative costs, and the inherent expenses of bringing novel biotherapeutics to market. The company generated a free cash flow of $-12,959,125, which signifies that operating cash flows are currently insufficient to cover capital expenditures, necessitating external financing or the utilization of existing cash reserves to fund ongoing operations. Analyzing the profit margins, the gross margin stands at -29.3%, the operating margin is -1755.5%, and the profit margin is -76.6%, all of which indicate that the company is not yet profitable on a per-unit basis and is burning cash to scale its technology. Regarding liquidity, Zymeworks holds $228.80M in cash against $18.27M in debt, resulting in a debt-to-equity ratio of 6.80 and a current ratio of 5.88. The elevated current ratio of 5.88 suggests that the company possesses a robust short-term liquidity position with current assets significantly exceeding current liabilities, providing a substantial buffer against operational disruptions. The return on equity is -26.7% and the return on assets is -14.3%, metrics that collectively reveal that management is currently sacrificing immediate shareholder returns to prioritize long-term asset accumulation and pipeline development rather than generating positive returns in the short term.
Waarderingsbeoordeling
Zymeworks presents a valuation profile where the trailing P/E ratio is N/A due to negative earnings, while the forward P/E is 33.43, implying that the market is pricing in a significant expected turnaround in earnings trajectory over the next twelve months. The price-to-book ratio stands at 7.32, indicating that the market is valuing the company at a substantial premium over its book value, likely reflecting the intangible value of its intellectual property and pipeline potential. Alternative valuation metrics show a price-to-sales ratio of 18.46 and an EV/EBITDA of -20.40, which suggests the market is valuing the firm based on revenue multiples rather than earnings, a common practice for unprofitable biotechnology companies with promising drug candidates. The stock has traded between a 52-week high of $28.49 and a 52-week low of $10.69, and without the current price explicitly listed in the facts, the range establishes a volatility band within which the company's share price fluctuates based on clinical trial results and market sentiment. The beta value is 1.20, which indicates that the stock's price volatility is 20% higher than the broader market, exposing investors to greater systematic risk than standard equity instruments.
Growth & Income
The company experienced a revenue growth year-over-year of -91.9%, while the earnings growth is N/A due to the lack of prior-year earnings for comparison or continued negative performance. This negative revenue growth rate suggests a contraction in sales or a shift in the commercialization phase of its products, which is often observed as companies pivot from clinical trials to market entry or manage limited commercial portfolios. As a non-dividend payer, Zymeworks maintains a dividend yield of N/A and a payout ratio of 0.0%, confirming that the company reinvests all available resources and any generated cash flow back into its research and development initiatives rather than distributing income to shareholders. The overall growth and income profile is characterized by significant revenue contraction and a complete absence of dividend income, reflecting a strategic focus on capitalizing on future clinical success rather than providing current cash returns to investors.